Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verve Therapeutics Inc
(NQ:
VERV
)
5.520
+0.410 (+8.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 02, 2024
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 02, 2024
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
Verve Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
April 02, 2024
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
April 02, 2024
From
Schall Law
Via
GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
April 02, 2024
The company is now pausing enrollment in the study of its lead asset, VERVE-101.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
March 21, 2024
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
Via
InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
February 19, 2024
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
Via
InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
February 13, 2024
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.
Via
InvestorPlace
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
February 12, 2024
It's less scary to take on risky investments when the market is rising.
Via
The Motley Fool
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
January 31, 2024
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.
Via
InvestorPlace
Why Beam Therapeutics Stock Zoomed 17% Higher Today
January 29, 2024
JPMorgan Chase becomes the latest institution in the company's bull pen.
Via
The Motley Fool
7 Mighty Healthcare Stocks Changing the Game of Medicine
January 17, 2024
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.
Via
InvestorPlace
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Via
InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
December 31, 2023
Curing rare inherited illnesses could be a lucrative business model.
Via
The Motley Fool
$18M Bet On Verve Therapeutics? Check Out These 3 Stocks Insiders Are Buying
December 06, 2023
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
December 01, 2023
From
Verve Therapeutics
Via
GlobeNewswire
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 29, 2023
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS...
Via
Benzinga
Why Verve Therapeutics Stock (VERV) Is Falling
November 29, 2023
Verve Therapeutics Inc (NASDAQ: VERV) shares are trading lower by 6.3% to $11.18 Wednesday morning after the company priced its proposed public offering of common stock and
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.